Developer docs
API playgroundTry for free, no card

Search company profiles

Zevra Therapeutics

Full company profile

uuid00005t2

Namestring
Zevra Therapeutics
Legal namestring
Zevra Therapeutics, Inc.
Websiteurl
zevra.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a commercial-stage rare disease biopharmaceutical company headquartered in Boston, Massachusetts with additional operations in Celebration, Florida and Frederiksberg, Denmark. The company, formerly KemPharm, Inc., pivoted from its prodrug heritage to rare disease drug development in January 2022, was renamed Zevra Therapeutics on Rare Disease Day 2023, and built its current portfolio through two acquisitions: Orphazyme A/S (May 2022, arimoclomol) and Acer Therapeutics (November 2023, OLPRUVA and celiprolol). Its two FDA-approved commercial products are MIPLYFFA (arimoclomol), the first and only approved treatment for Niemann-Pick disease type C (NPC) in adult and pediatric patients aged 2 and older, used in combination with miglustat; and OLPRUVA (sodium phenylbutyrate), a dual-coated oral suspension for certain urea cycle disorders. A third program, celiprolol, is in Phase 3 development (DiSCOVER trial) for COL3A1-positive vascular Ehlers-Danlos syndrome (VEDS).

The company's underlying technology combines a proprietary Ligand Activated Therapy (LAT) prodrug platform — inherited from KemPharm — with rare disease drug development capabilities, including arimoclomol's novel heat shock protein amplification mechanism that addresses lysosomal dysfunction and celiprolol's selective adrenoceptor modulation that reduces mechanical stress on vascular walls. Real-world data generation through a multi-year U.S. and international Expanded Access Program (covering 122 and 113 patients respectively) is used to inform both clinical development strategy and payer engagement.

Zevra operates a specialty pharmaceutical commercial model: a direct specialty sales force targets healthcare professionals treating patients with NPC, UCDs, and VEDS; distribution in the U.S. runs through an exclusive specialty pharmacy arrangement with Orsini, while international distribution outside Europe is handled by Uniphar under a December 2025 exclusive agreement. Revenue is generated from commercial product sales (MIPLYFFA U.S. net sales of $24.6 million in Q1 2026), Expanded Access Program reimbursements ($10.2 million in Q1 2026), and one-time divestiture proceeds (the $50 million SDX portfolio sale to Commave Therapeutics in March 2026). FY2025 total net revenue reached $106.5 million (up 350% year-over-year), the company reported $83.2 million in net income, and as of Q1 2026 it held $236.8 million in cash with no outstanding debt after fully repaying a $63 million term loan.

Short descriptiontext

Zevra Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing therapies for rare diseases, including the first FDA-approved treatment for Niemann-Pick disease type C (MIPLYFFA), an approved urea cycle disorder therapy (OLPRUVA), and a Phase 3 asset (celiprolol) for vascular Ehlers-Danlos syndrome.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, specialty pharmaceuticals, CNS drug development, prodrug technology platform, orphan disease treatments
Industry2 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Therapeutics
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Commercial product sales
TypeHardware Sales
Description

Direct sales of approved pharmaceutical products MIPLYFFA (arimoclomol) for NPC and OLPRUVA (sodium phenylbutyrate) for UCDs; Q1 2026 US MyPlifer net sales of $24.6 million

fool.com
2Expanded Access Program (EAP) reimbursements
TypeManaged Services
Description

Reimbursements from expanded access programs covering 122 patients across multiple territories; $10.2 million in Q1 2026; 113 international patients enrolled

fool.com
3Asset divestiture (one-time)
TypeOne Time License
Description

Sale of SDX portfolio including AZSTARYS and KP1077 to Commave Therapeutics for $50 million in March 2026 as part of litigation settlement and balance sheet restructuring

stocktitan.net
4Royalty income (third-party)
TypeLicensing Royalties
Description

Royalties received from third parties (Xoma Royalty/Ligand) tied to Miplyffa commercial sales as part of historical royalty monetization arrangements

fiercepharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Specialty pharmacy pricing for MIPLYFFA via Orsini
ModelOther
Notes

Pricing not publicly disclosed; reimbursement-based model through specialty pharmacy distribution

openpr.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MIPLYFFA
Description

U.S. FDA-approved treatment (arimoclomol) for neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older, used in combination with miglustat.

zevra.com
+1 more record
Core offering1 text field

Zevra Therapeutics is a commercial-stage rare disease biopharmaceutical company that develops and commercializes therapies for ultra-rare diseases. Its portfolio includes two FDA-approved products: MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company also has a late-stage pipeline asset, celiprolol, in a Phase 3 trial for Vascular Ehlers-Danlos Syndrome (VEDS). Distribution is conducted via a specialty pharmacy (Orsini) in the US and an international distribution partner (Uniphar) outside Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • FY2025 revenue growth of 350% year-over-year to $106.5 million
+6 more records
Product overview1 text field

Zevra Therapeutics operates a focused rare disease therapeutics portfolio rather than a unified software platform. The offering centers on two FDA-approved commercial products — MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C and OLPRUVA® (sodium phenylbutyrate) for certain urea cycle disorders — complemented by a late-stage clinical asset, Celiprolol, currently in a Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome (VEDS). Arimoclomol is also progressing through a Marketing Authorization Application review with the European Medicines Agency to expand the NPC franchise internationally. The portfolio was assembled through two key acquisitions: Orphazyme A/S (May 2022, brought arimoclomol) and Acer Therapeutics (November 2023, brought OLPRUVA and celiprolol), positioning Zevra as a commercial-stage rare disease company executing on commercial excellence for MIPLYFFA and OLPRUVA while advancing its clinical pipeline.

Product and service3 records
1MIPLYFFA (arimoclomol)
CategoryCommercial product (approved)
Description

First U.S. FDA-approved treatment for Niemann-Pick disease type C (NPC); an orally-delivered, first-in-class therapy indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older.

2OLPRUVA (sodium phenylbutyrate)
CategoryCommercial product (approved)
Description

U.S. FDA-approved dual-coated sodium phenylbutyrate oral suspension for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

3Celiprolol
CategoryLate-stage clinical asset (Phase 3)
Description

Investigational selective adrenoceptor modulator being evaluated in the Phase 3 DiSCOVER trial for the treatment of COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS), enrolling 150 patients with up to 400 mg/day dosing. Believed to decrease mechanical stress on the vascular wall of large arteries and hollow organs.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1GeneDx Holdings Corp.
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-20
Description

GeneDx and Zevra Therapeutics announced a partnership in March 2026 to launch a sponsored genetic testing program for Niemann-Pick disease type C (NPC) in the US. The program leverages GeneDx's ExomeDx test and rare-disease genomic dataset (GeneDx Infinity) to help diagnose NPC more quickly and integrate data into a large genomic dataset, with Zevra providing financial support.

finance.yahoo.com
2Commave Therapeutics
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-16
Description

In March 2026, Zevra Therapeutics sold its entire SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million. The transaction also resolves pending litigation between the two companies stemming from a 2019 license agreement, with Commave having initiated legal action in Delaware Chancery Court in 2024. Zevra also repaid its $63 million term loan in full prior to the agreement, leaving the company debt-free.

stocktitan.net
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-29
Description

In December 2025, Zevra Therapeutics signed an exclusive distribution agreement with Uniphar to expand access to MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C patients outside of Europe. The agreement supports Zevra's US and EU regulatory strategies and aims to improve patient access globally.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-01
Description

In September 2024, Zevra Therapeutics partnered with Orsini to become the exclusive specialty pharmacy provider for MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C. The partnership aims to expand patient access to the therapy through specialty pharmacy distribution and reimbursement support in the United States.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

In November 2023, Zevra completed the acquisition of Acer Therapeutics, Inc., including the U.S. FDA-approved OLPRUVA® for the treatment of certain urea cycle disorders, and celiprolol, an investigational product for the treatment of vascular Ehlers-Danlos syndrome. Through Acer's existing infrastructure, Zevra efficiently emerged as a commercial-stage organization and quickly launched OLPRUVA in January 2024.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

In May 2022, Zevra (then KemPharm) acquired substantially all of the assets of Orphazyme, A/S, a Denmark-based company focused on neurological rare diseases. The acquisition included arimoclomol, a product candidate intended for the treatment of Niemann-Pick disease type C (NPC), and welcomed many of Orphazyme's team members. Arimoclomol became the basis for MIPLYFFA, the first FDA-approved NPC treatment.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage rare disease biopharma with multiple approved and late-stage therapies for ultra-rare genetic disorders, comparable in commercial focus on specialty distribution, payer coverage strategies, and orphan pricing model.

TypeDirect peer
Description

Focused commercial rare disease company with FDA-approved therapies for cholestatic liver diseases, sharing the specialty pharmacy distribution model and orphan disease commercial playbook.

TypeDirect peer
Description

Commercial-stage rare disease biopharma with approved therapies for ultra-rare conditions (previously Retrophin), where Neil McFarlane served as COO; comparable in therapeutic area focus and rare disease commercial approach.

TypeDirect peer
Description

Commercial rare disease biopharma with Galafold for Fabry disease and Pombiliti+Opfolda for Pompe, comparable in patient identification, genetic testing partnerships, and ultra-rare specialty distribution model.

TypeBroad incumbent
Description

Larger established rare disease biopharma with broad portfolio across multiple rare genetic conditions including enzyme replacement therapies; relevant given BioMarin executive Josh Schafer's background and overlap in rare metabolic disease commercial model.

TypeDirect peer
Description

RNA-targeted rare disease biopharma with multiple approved and late-stage neurological assets, comparable in CNS-focused rare disease development and platform-based drug development approach.

TypeDirect peer
Description

Clinical and commercial-stage rare genetic disease company with approved Attruby for transthyretin amyloid cardiomyopathy and pipeline in Mendelian diseases; comparable in rare disease commercial model and genetic testing-driven patient identification.

TypeBroad incumbent
Description

Large established European rare disease biopharma with broad portfolio in hematology, immunology, and specialty care; comparable in European rare disease commercial strategy relevant to Zevra's EMA MAA expansion.

TypeBroad incumbent
Description

Global leader in rare disease commercial execution with Soliris/Ultomiris franchise and broader AstraZeneca rare disease portfolio, comparable as the gold standard for ultra-rare specialty pharmacy distribution and orphan pricing.

TypeOthers
Description

Specialty pharma with autoimmune and rare disease focus including autoimmune neurology franchise; comparable through executive overlap (Joshua Schafer's prior GM role) and specialty distribution model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zevra Therapeutics

Rare Disease Therapeuticszevra.com

Zevra Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing therapies for rare diseases, including the first FDA-approved treatment for Niemann-Pick disease type C (MIPLYFFA), an approved urea cycle disorder therapy (OLPRUVA), and a Phase 3 asset (celiprolol) for vascular Ehlers-Danlos syndrome.

What Zevra Therapeutics does

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a commercial-stage rare disease biopharmaceutical company headquartered in Boston, Massachusetts with additional operations in Celebration, Florida and Frederiksberg, Denmark. The company, formerly KemPharm, Inc., pivoted from its prodrug heritage to rare disease drug development in January 2022, was renamed Zevra Therapeutics on Rare Disease Day 2023, and built its current portfolio through two acquisitions: Orphazyme A/S (May 2022, arimoclomol) and Acer Therapeutics (November 2023, OLPRUVA and celiprolol). Its two FDA-approved commercial products are MIPLYFFA (arimoclomol), the first and only approved treatment for Niemann-Pick disease type C (NPC) in adult and pediatric patients aged 2 and older, used in combination with miglustat; and OLPRUVA (sodium phenylbutyrate), a dual-coated oral suspension for certain urea cycle disorders. A third program, celiprolol, is in Phase 3 development (DiSCOVER trial) for COL3A1-positive vascular Ehlers-Danlos syndrome (VEDS).

The company's underlying technology combines a proprietary Ligand Activated Therapy (LAT) prodrug platform — inherited from KemPharm — with rare disease drug development capabilities, including arimoclomol's novel heat shock protein amplification mechanism that addresses lysosomal dysfunction and celiprolol's selective adrenoceptor modulation that reduces mechanical stress on vascular walls. Real-world data generation through a multi-year U.S. and international Expanded Access Program (covering 122 and 113 patients respectively) is used to inform both clinical development strategy and payer engagement.

Zevra operates a specialty pharmaceutical commercial model: a direct specialty sales force targets healthcare professionals treating patients with NPC, UCDs, and VEDS; distribution in the U.S. runs through an exclusive specialty pharmacy arrangement with Orsini, while international distribution outside Europe is handled by Uniphar under a December 2025 exclusive agreement. Revenue is generated from commercial product sales (MIPLYFFA U.S. net sales of $24.6 million in Q1 2026), Expanded Access Program reimbursements ($10.2 million in Q1 2026), and one-time divestiture proceeds (the $50 million SDX portfolio sale to Commave Therapeutics in March 2026). FY2025 total net revenue reached $106.5 million (up 350% year-over-year), the company reported $83.2 million in net income, and as of Q1 2026 it held $236.8 million in cash with no outstanding debt after fully repaying a $63 million term loan.

Zevra Therapeutics firmographics

Firmographics
Name
Zevra Therapeutics
Legal name
Zevra Therapeutics, Inc.
Website
https://zevra.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Zevra Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing therapies for rare diseases, including the first FDA-approved treatment for Niemann-Pick disease type C (MIPLYFFA), an approved urea cycle disorder therapy (OLPRUVA), and a Phase 3 asset (celiprolol) for vascular Ehlers-Danlos syndrome.
Ownership category
akta.pro rank

Zevra Therapeutics industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Specialty pharmaceuticals
  • CNS drug development
  • Prodrug technology platform
  • Orphan disease treatments

Where Zevra Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Zevra Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Commercial product sales: Direct sales of approved pharmaceutical products MIPLYFFA (arimoclomol) for NPC and OLPRUVA (sodium phenylbutyrate) for UCDs; Q1 2026 US MyPlifer net sales of $24.6 million
  2. Expanded Access Program (EAP) reimbursements: Reimbursements from expanded access programs covering 122 patients across multiple territories; $10.2 million in Q1 2026; 113 international patients enrolled
  3. Asset divestiture (one-time): Sale of SDX portfolio including AZSTARYS and KP1077 to Commave Therapeutics for $50 million in March 2026 as part of litigation settlement and balance sheet restructuring
  4. Royalty income (third-party): Royalties received from third parties (Xoma Royalty/Ligand) tied to Miplyffa commercial sales as part of historical royalty monetization arrangements

Pricing tiers

ModelBillingPrice
Other—Specialty pharmacy pricing for MIPLYFFA via Orsini

Go-to-market motion5 records

Distribution channels5 records

Marketing channels7 records

Zevra Therapeutics product offering

Product offering

Core offering

Zevra Therapeutics is a commercial-stage rare disease biopharmaceutical company that develops and commercializes therapies for ultra-rare diseases. Its portfolio includes two FDA-approved products: MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company also has a late-stage pipeline asset, celiprolol, in a Phase 3 trial for Vascular Ehlers-Danlos Syndrome (VEDS). Distribution is conducted via a specialty pharmacy (Orsini) in the US and an international distribution partner (Uniphar) outside Europe.

Product overview

Zevra Therapeutics operates a focused rare disease therapeutics portfolio rather than a unified software platform. The offering centers on two FDA-approved commercial products — MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C and OLPRUVA® (sodium phenylbutyrate) for certain urea cycle disorders — complemented by a late-stage clinical asset, Celiprolol, currently in a Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome (VEDS). Arimoclomol is also progressing through a Marketing Authorization Application review with the European Medicines Agency to expand the NPC franchise internationally. The portfolio was assembled through two key acquisitions: Orphazyme A/S (May 2022, brought arimoclomol) and Acer Therapeutics (November 2023, brought OLPRUVA and celiprolol), positioning Zevra as a commercial-stage rare disease company executing on commercial excellence for MIPLYFFA and OLPRUVA while advancing its clinical pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • MIPLYFFA: U.S. FDA-approved treatment (arimoclomol) for neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older, used in combination with miglustat.
  • OLPRUVA

Products and services

  • MIPLYFFA (arimoclomol) First U.S. FDA-approved treatment for Niemann-Pick disease type C (NPC); an orally-delivered, first-in-class therapy indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older.
  • OLPRUVA (sodium phenylbutyrate) U.S. FDA-approved dual-coated sodium phenylbutyrate oral suspension for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
  • Celiprolol Investigational selective adrenoceptor modulator being evaluated in the Phase 3 DiSCOVER trial for the treatment of COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS), enrolling 150 patients with up to 400 mg/day dosing. Believed to decrease mechanical stress on the vascular wall of large arteries and hollow organs.

Quantifiable outcome

  • FY2025 revenue growth of 350% year-over-year to $106.5 million
  • +6 more outcomes

Companies that use Zevra Therapeutics

Customer profile

Segments5 records

Ideal customer profiles1 record

Zevra Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Zevra Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and major.

  • GeneDx Holdings Corp.flagshipStrategic or Co-development Partner · 20 March 2026GeneDx and Zevra Therapeutics announced a partnership in March 2026 to launch a sponsored genetic testing program for Niemann-Pick disease type C (NPC) in the US. The program leverages GeneDx's ExomeDx test and rare-disease genomic dataset (GeneDx Infinity) to help diagnose NPC more quickly and integrate data into a large genomic dataset, with Zevra providing financial support.
  • Commave TherapeuticsmajorStrategic or Co-development Partner · 16 March 2026In March 2026, Zevra Therapeutics sold its entire SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million. The transaction also resolves pending litigation between the two companies stemming from a 2019 license agreement, with Commave having initiated legal action in Delaware Chancery Court in 2024. Zevra also repaid its $63 million term loan in full prior to the agreement, leaving the company debt-free.
  • UnipharflagshipChannel Partner/ Reseller/ Distributor · 29 December 2025In December 2025, Zevra Therapeutics signed an exclusive distribution agreement with Uniphar to expand access to MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C patients outside of Europe. The agreement supports Zevra's US and EU regulatory strategies and aims to improve patient access globally.
  • OrsiniflagshipChannel Partner/ Reseller/ Distributor · 1 September 2024In September 2024, Zevra Therapeutics partnered with Orsini to become the exclusive specialty pharmacy provider for MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C. The partnership aims to expand patient access to the therapy through specialty pharmacy distribution and reimbursement support in the United States.
  • Acer Therapeutics, Inc.flagshipStrategic or Co-development Partner · 1 November 2023In November 2023, Zevra completed the acquisition of Acer Therapeutics, Inc., including the U.S. FDA-approved OLPRUVA® for the treatment of certain urea cycle disorders, and celiprolol, an investigational product for the treatment of vascular Ehlers-Danlos syndrome. Through Acer's existing infrastructure, Zevra efficiently emerged as a commercial-stage organization and quickly launched OLPRUVA in January 2024.
  • Orphazyme, A/SflagshipStrategic or Co-development Partner · 1 May 2022In May 2022, Zevra (then KemPharm) acquired substantially all of the assets of Orphazyme, A/S, a Denmark-based company focused on neurological rare diseases. The acquisition included arimoclomol, a product candidate intended for the treatment of Niemann-Pick disease type C (NPC), and welcomed many of Orphazyme's team members. Arimoclomol became the basis for MIPLYFFA, the first FDA-approved NPC treatment.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Zevra Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biopharma with multiple approved and late-stage therapies for ultra-rare genetic disorders, comparable in commercial focus on specialty distribution, payer coverage strategies, and orphan pricing model.
  • Mirum Pharmaceuticals: Focused commercial rare disease company with FDA-approved therapies for cholestatic liver diseases, sharing the specialty pharmacy distribution model and orphan disease commercial playbook.
  • Travere Therapeutics: Commercial-stage rare disease biopharma with approved therapies for ultra-rare conditions (previously Retrophin), where Neil McFarlane served as COO; comparable in therapeutic area focus and rare disease commercial approach.
  • Amicus Therapeutics: Commercial rare disease biopharma with Galafold for Fabry disease and Pombiliti+Opfolda for Pompe, comparable in patient identification, genetic testing partnerships, and ultra-rare specialty distribution model.
  • Ionis Pharmaceuticals: RNA-targeted rare disease biopharma with multiple approved and late-stage neurological assets, comparable in CNS-focused rare disease development and platform-based drug development approach.
  • BridgeBio Pharma: Clinical and commercial-stage rare genetic disease company with approved Attruby for transthyretin amyloid cardiomyopathy and pipeline in Mendelian diseases; comparable in rare disease commercial model and genetic testing-driven patient identification.

Broad incumbents

  • BioMarin Pharmaceutical: Larger established rare disease biopharma with broad portfolio across multiple rare genetic conditions including enzyme replacement therapies; relevant given BioMarin executive Josh Schafer's background and overlap in rare metabolic disease commercial model.
  • Swedish Orphan Biovitrum (Sobi): Large established European rare disease biopharma with broad portfolio in hematology, immunology, and specialty care; comparable in European rare disease commercial strategy relevant to Zevra's EMA MAA expansion.
  • Alexion (AstraZeneca Rare Disease): Global leader in rare disease commercial execution with Soliris/Ultomiris franchise and broader AstraZeneca rare disease portfolio, comparable as the gold standard for ultra-rare specialty pharmacy distribution and orphan pricing.

Others

  • Mallinckrodt Pharmaceuticals: Specialty pharma with autoimmune and rare disease focus including autoimmune neurology franchise; comparable through executive overlap (Joshua Schafer's prior GM role) and specialty distribution model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Zevra Therapeutics social profiles

Digital presence

Zevra Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zevra Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Zevra Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Zevra Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zevra Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zevra Therapeutics

What does Zevra Therapeutics do?

Zevra Therapeutics is a commercial-stage rare disease biopharmaceutical company that develops and commercializes therapies for ultra-rare diseases. Its portfolio includes two FDA-approved products: MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company also has a late-stage pipeline asset, celiprolol, in a Phase 3 trial for Vascular Ehlers-Danlos Syndrome (VEDS). Distribution is conducted via a specialty pharmacy (Orsini) in the US and an international distribution partner (Uniphar) outside Europe.

Is Zevra Therapeutics a public or private company?

Zevra Therapeutics is a public company. It is classified as public and is currently operating.

When was Zevra Therapeutics founded?

Zevra Therapeutics was founded in 2022. It employs 51 to 100 people.

Where is Zevra Therapeutics based?

Zevra Therapeutics is headquartered in Boston, United States, in the North America region.

How does Zevra Therapeutics make money?

Four revenue lines are on record. Commercial product sales are the primary driver. The others are expanded Access Program (EAP) reimbursements, asset divestiture (one-time) and royalty income (third-party).

Who are Zevra Therapeutics's main competitors?

Direct peers on record are Ultragenyx Pharmaceutical, Mirum Pharmaceuticals, Travere Therapeutics, Amicus Therapeutics, Ionis Pharmaceuticals and BridgeBio Pharma. Broad incumbents are BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi) and Alexion (AstraZeneca Rare Disease). Mallinckrodt Pharmaceuticals is listed as an others.

Does Zevra Therapeutics have an API?

No public API is recorded for Zevra Therapeutics.

What industry is Zevra Therapeutics in?

Zevra Therapeutics's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewGuggenheim maintains Zevra Therapeutics at Buy, lowers price target to $18 from $23Guggenheim maintained Zevra Therapeutics at Buy and lowered its price target to $18 from $23, a 21.7% decrease. The target implies an upside of 98.2% from the Nov 13 close of $9.08.TradingViewBTIG maintains Zevra Therapeutics at Buy, lowers price target to $21 from $24BTIG maintained Zevra Therapeutics at Buy and lowered its price target to $21 from $24, a 12.5% decrease. The target implies an upside of 88.2% from the Nov 12 close of $11.16.TradingViewCantor Fitzgerald maintains Zevra Therapeutics at Overweight, lowers price target to $19 from $25Cantor Fitzgerald maintained Zevra Therapeutics at Overweight and lowered its price target to $19 from $25, a 24% decrease. The target implies 70.3% upside from the Nov 12 close of $11.16.MarketWatchEuropean Drug Regulator Recommends Against Approving Zevra Therapeutics' Drug for Neurodegenerative DisorderEuropean drug regulators recommended against approving Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C. The European Medicines Agency's CHMP issued a negative opinion, and Zevra expects a final decision within 67 days. Zevra will continue its expanded access program and advance research.TradingViewZevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European UnionZevra Therapeutics announced the EMA's CHMP adopted a negative opinion on arimoclomol's MAA for Niemann-Pick disease type C, with the European Commission expected to decide within 67 days. The company will continue its Expanded Access Program for eligible patients. Zevra remains focused on supporting patients and advancing scientific understanding.TradingViewZevra Therapeutics (ZVRA) Receives Negative EU Opinion on ArimoclomolThe EMA's CHMP adopted a negative opinion on Zevra Therapeutics' EU marketing application for arimoclomol. The European Commission is expected to issue its final decision within 67 days, which will determine whether the application can proceed to authorization. Zevra will continue its expanded access program subject to regulatory requirements.ChartmillZevra Therapeutics (NASDAQ:ZVRA) Clears All Eight Growth RulesZevra Therapeutics clears all eight growth rules from Louis Navellier's methodology, with EPS revisions up 30.29% and EPS growth of 1,900% quarter over quarter. The company receives a 6/10 fundamental rating, citing strong growth and neutral valuation, though it reports negative net income in four of the past five years.Seeking AlphaZevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4 (NASDAQ:ZVRA)Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, with $34 million from MIPLYFFA U.S. sales. The company expects to file an sNDA for infant label expansion in Q1 2027 and anticipates a CHMP opinion in Q4. Celiprolol enrollment reached 72 patients with four confirmed events.TradingViewZevra Therapeutics 3Q 2026: Revenue $37.76M, Net income $19.21M, EPS $0.26— 10-Q SummaryZevra Therapeutics reported third-quarter 2026 revenue of $37.76 million and net income of $19.21 million, up 44.9% and 3,630.9% year over year, respectively. Diluted EPS was $0.26 versus a loss of $0.01 per share. The company also noted a negative CHMP opinion on arimoclomol and ongoing Phase 3 DiSCOVER trial.Seeking AlphaZevra Therapeutics, Inc. GAAP EPS of $0.26 beats by $0.11, revenue of $37.8M beats by $0.39M (ZVRA:NASDAQ)Zevra Therapeutics reported Q3 2026 GAAP EPS of $0.26, beating estimates by $0.11, and revenue of $37.8 million, up 44.8% year-over-year and beating by $0.39 million. Operating expenses totaled $24.1 million, with R&D at $4.9 million and SG&A at $19.1 million.